ArticleCancer medicine2026
Mitochondrial Genomic Alterations in Pediatric Acute Lymphoblastic Leukemia: Implications for Methotrexate-Induced Neurotoxicity and Ethnic Disparities.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Methotrexate (MTX)-induced neurotoxicity is a serious complication in pediatric acute lymphoblastic leukemia (ALL), with observed ethnic disparities in risk. To investigate the role of mitochondrial DNA (mtDNA) variation, we performed whole mtDNA sequencing in 94 children with ALL, including 62 Hispanic patients. We identified 1294 mtDNA variants, including 12.4% novel variants, with MT-ND5 and the D-loop representing major variant hotspots. Gene-based analyses identified significant associations of MT-ND6 and MT-ND2 with MTX neurotoxicity after multiple testing correction. Heteroplasmy was more frequent in affected patients, and predictive models incorporating mtDNA variants improved discrimination (AUC = 0.78) compared with clinical factors alone. These findings suggest that mtDNA variation, particularly involving Complex I genes, may contribute to MTX neurotoxicity and support its potential utility for risk stratification, while requiring validation in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.